| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
DL-Cloprostenol sodium is an agonist of the prostaglandin F2α (PGF2α) receptor. It selectively binds to and activates this GPCR, which mediates its luteolytic effects on the corpus luteum.
|
|---|---|
| ln Vitro |
Cloprostenol is an agonist of the PGF2α receptor (2]. The adipogenic effects of statil on intracellular lipid accumulation and transcript expression of the pro-adipogenic factors C/EBPα and PPARγ were countered by cloprostenol (0.1 μM) after 6 days of therapy [2].
Cloprostenol (0.1 μM) countered the adipogenic effects of statil on intracellular lipid accumulation and transcript expression of pro-adipogenic factors C/EBPα and PPARγ after 6 days of therapy. It exhibits potent activity with 200-fold and 100-fold greater potency than PGF2α in terminating pregnancy in hamsters and rats, respectively. |
| ln Vivo |
In pregnant rats, cloprostenol sodium salt (25 μg) lowers plasma progesterone [1].
In pregnant rats, cloprostenol sodium salt (25 μg) decreases plasma progesterone. This in vivo luteolytic effect underlies its use for estrus synchronization in cattle. The compound reduces serum progesterone levels, leading to regression of the corpus luteum. |
| Enzyme Assay |
In vitro receptor binding assays typically use membrane preparations from cells expressing the PGF2α receptor. Radiolabeled PGF2α is displaced by increasing concentrations of DL-Cloprostenol sodium to determine binding affinity (Ki). Non-specific binding is determined in the presence of excess unlabeled ligand, and bound radioactivity is measured by scintillation counting or filtration methods.
|
| Cell Assay |
Cell-based functional assays utilize cells endogenously or heterologously expressing the PGF2α receptor. Cells are seeded in multi-well plates and treated with varying concentrations of DL-Cloprostenol sodium. Intracellular calcium mobilization or cAMP inhibition (downstream of Gq or Gi signaling) is measured using fluorescent dyes or luminescent assays. EC50 values are calculated from dose-response curves.
|
| Animal Protocol |
In vivo animal studies typically involve administration of DL-Cloprostenol sodium to pregnant rats or hamsters. The compound is injected subcutaneously or intramuscularly at doses ranging from 10-100 μg per animal. Plasma progesterone levels are measured by radioimmunoassay at various time points post-administration. Efficacy is assessed by pregnancy termination rate and luteal regression confirmed by ovarian histology.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for DL-Cloprostenol sodium are characteristic of prostaglandin analogs. Following parenteral administration, it is rapidly absorbed and distributed. The compound undergoes extensive metabolism via oxidation and reduction, with a relatively short half-life in circulation. Excretion occurs primarily through renal pathways, with metabolites eliminated in urine and feces.
|
| Toxicity/Toxicokinetics |
The toxicological profile of DL-Cloprostenol sodium is typical of prostaglandin F2α analogs. At therapeutic doses, common side effects include mild gastrointestinal disturbances, transient fever, and local injection site reactions. Higher doses may cause bronchoconstriction, vasoconstriction, and uterine cramping. The compound has a moderate safety margin in animal models, with adverse effects generally reversible upon cessation of treatment.
|
| References |
|
| Additional Infomation |
A synthetic prostaglandin F2α analog. This compound has luteolytic activity and is used for estrus synchronization in cattle.
See also: cloprostenol (containing the active moiety). DL-Cloprostenol sodium is widely used in veterinary medicine for estrus synchronization and reproductive management in cattle, pigs, and horses. It is not approved for human therapeutic use. The compound is a racemic mixture, with the D-isomer being the more biologically active enantiomer. Research applications include studying prostaglandin receptor signaling, luteal function, and reproductive physiology. |
| Molecular Formula |
C22H28CLNAO6
|
|---|---|
| Molecular Weight |
446.8998
|
| Exact Mass |
446.147
|
| CAS # |
55028-72-3
|
| Related CAS # |
40665-92-7 (Parent)
|
| PubChem CID |
17756794
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
628ºC at 760 mmHg
|
| Melting Point |
68-70ºC
|
| Flash Point |
333.6ºC
|
| LogP |
1.86
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
30
|
| Complexity |
558
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1[C@@H]([C@@H]([C@H]([C@@H]1O)/C=C/[C@H](COC2=CC(=CC=C2)Cl)O)C/C=C\CCCC(=O)[O-])O.[Na+]
|
| InChi Key |
IFEJLMHZNQJGQU-KXXGZHCCSA-M
|
| InChi Code |
InChI=1S/C22H29ClO6.Na/c23-15-6-5-7-17(12-15)29-14-16(24)10-11-19-18(20(25)13-21(19)26)8-3-1-2-4-9-22(27)28;/h1,3,5-7,10-12,16,18-21,24-26H,2,4,8-9,13-14H2,(H,27,28);/q;+1/p-1/b3-1-,11-10+;/t16-,18-,19-,20+,21-;/m1./s1
|
| Chemical Name |
sodium;(Z)-7-[(1R,2R,3R,5S)-2-[(E,3R)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate
|
| Synonyms |
ICI 80996; ICI-80996; ICI 80996
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 150 mg/mL (~335.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (223.76 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2376 mL | 11.1882 mL | 22.3764 mL | |
| 5 mM | 0.4475 mL | 2.2376 mL | 4.4753 mL | |
| 10 mM | 0.2238 mL | 1.1188 mL | 2.2376 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
